Restorative strategies for the dopaminergic nigrostriatal projection pathway

Acta Neurochirurgica, Supplementum

Volumn 117, Issue , 2013, Pages 79-85

  Nikkhah, Guido ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Fetal and stem cell transplantation; Neuroprotection; Parkinson's disease

Indexed keywords

ALPHA TOCOPHEROL; DOPAMINE RECEPTOR STIMULATING AGENT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE RECEPTOR ANTAGONIST; PERGOLIDE; SELEGILINE;

ARTICLE; CELL TRANSPLANTATION; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; HEADACHE; HUMAN; HYPERTENSION; NERVE CELL DEGENERATION; NERVE PROJECTION; NERVE REGENERATION; NEURAL STEM CELL; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; STRIATONIGRAL DEGENERATION; TACHYCARDIA; TISSUE TRANSPLANTATION; VOMITING;

EID: 85052609299     PISSN: 00651419     EISSN: 00016268     Source Type: Book Series    
DOI: 10.1007/978-3-7091-1482-7_13     Document Type: Article

References (55)

1. Aron L, Klein R (2011) Repairing the parkinsonian brain with neurotrophic factors. Trends Neurosci 34:88-100
2. Backlund EO, Granberg PO, Hamberger B, Knutsson E, Martensson A, Sedvall G, Seiger A, Olson L (1985) Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J Neurosurg 62:169-173
3. Bergman H, Wichmann T, DeLong MR (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249:1436-1438
4. Blandini F, Porter RH, Greenamyre JT (1996) Glutamate and Parkinson's disease. Mol Neurobiol 12:73-94
5. Brundin P, Dunnett S, Bjorklund A, Nikkhah G (2001) Transplanted dopaminergic neurons: more or less? Nat Med 7:512-513
6. Capetian P, Döbrössy M, Winkler C, Prinz M, Nikkhah G (2011) To be or not to be accepted: the role of immunogenicity of neural stem cells following transplantation into the brain in animal and human studies. Semin Immunopathol 33:619-626
7. Carvalho GA, Nikkhah G (2001) Subthalamic nucleus lesions are neuroprotective against terminal 6-OHDA-induced striatal lesions and restore postural balancing reactions. Exp Neurol 171:405-417
8. Chevalier G, Deniau JM (1990) Disinhibition as a basic process in the expression of striatal functions. Trends Neurosci 13:277-280
9. Choi DW, Rothman SM (1990) The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci 13: 171-182
10. Döbrössy M, Busse M, Piroth T, Rosser A, Dunnett S, Nikkhah G (2010) Neurorehabilitation with neural transplantation. Neurorehabil Neural Repair 24:692-701
11. Dyson SC, Barker RA (2011) Cell-based therapies for Parkinson's disease. Expert Rev Neurother 11:831-844
12. Falkenstein G, Rosenthal C, Reum T, Morgenstern R, Döbrössy M, Nikkhah G (2009) Pattern of long-term sensorimotor recovery following intrastriatal and - accumbens DA micrografts in a rat model of Parkinson's disease. J Comp Neurol 515:41-55
13. Feger J, Hassani OK, Mouroux M (1997) The subthalamic nucleus and its connections. New electrophysiological and pharmacological data. Adv Neurol 74:31-43
14. Foley P, Riederer P (1999) Pathogenesis and preclinical course of Parkinson's disease. J Neural Transm Suppl 56:31-74
15. García J, Carlsson T, Döbrössy M, Nikkhah G, Winkler C (2011) Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia. Neurobiol Dis 43:576-587
16. Gash DM, Zhang Z, Gerhardt G (1998) Neuroprotective and neurorestorative properties of GDNF. Ann Neurol 44:S121-S125
17. Guridi J, Herrero MT, Luquin MR, Guillen J, Ruberg M, Laguna J, Vila M, Javoy-Agid F, Agid Y, Hirsch E, Obeso JA (1996) Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis. Brain 119(Pt 5):1717-1727
18. Guridi J, Obeso JA (1997) The role of the subthalamic nucleus in the origin of hemiballism and parkinsonism: new surgical perspectives. Adv Neurol 74:235-247
19. Halliday G, Lees A, Stern M (2011) Milestones in Parkinson's disease - clinical and pathologic features. Mov Dis 26:1015-1021
20. Hassani OK, Mouroux M, Feger J (1996) Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus. Neuroscience 72:105-115
21. Isacson O (2009) Cell therapy ahead for Parkinson's disease. Science 326:1060
22. Kearns CM, Cass WA, Smoot K, Kryscio R, Gash DM (1997) GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis. J Neurosci 17:7111-7118
23. Koller W, Wilkinson S, Pahwa R et al (1998) Surgical treatment options in Parkinson's disease. In: Bakay R (ed) Neurosurgery clinics of North America: surgical treatment movement disorders. W. B. Saunders Company, Philadelphia, pp 295-306
24. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14(5):504-506
25. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, PalfiS, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, Trono D, Hantraye P, Deglon N, Aebischer P (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290:767-773
26. Lang AE, Lozano AM (1998) Parkinson's disease. Second of two parts. N Engl J Med 339:1130-1143
27. LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Van Meter L, Sapan CV, During MJ, Kaplitt MG, Feigin A (2011) AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 10:309-319
28. Levy R, Hazrati LN, Herrero MT, Vila M, Hassani OK, Mouroux M, Ruberg M, Asensi H, Agid Y, Feger J, Obeso JA, Parent A, Hirsch EC (1997) Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states. Neuroscience 76:335-343
29. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Bjorklund A, Widner H, Revesz T, Lindvall O, Brundin P (2008) Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14:501-503
30. Lindvall O, Björklund A (2011) Cell therapeutics in Parkinson's disease. Neurotherapeutics 8:539-548
31. Lindvall O, Kokaia Z (2010) Stem cells in human neurodegenerative disorders - time for clinical translation? J Clin Invest 120:29-40
32. Lindvall O, Rehncrona S, Brundin P, Gustavii B, Astedt B, Widner H, Lindholm T, Bjorklund A, Leenders KL, Rothwell JC, Frackowiak R, Marsden D, Johnels B, Steg G, Freedman R, Hoffer BJ, Seiger A, Bygdeman M, Strömberg I, Olson L (1989) Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch Neurol 46:615-631
33. Maciaczyk J, Singec I, Maciaczyk D, Nikkhah G (2008) Combined use of BDNF, ascorbic acid, low oxygen, and prolonged differentiation time generates tyrosine hydroxylase-expressing neurons after long-term in vitro expansion of human fetal midbrain precursor cells. Exp Neurol 213(2):354-362
34. Madrazo I, Drucker-Colin R, Diaz V, Martinez-Mata J, Torres C, Becerril JJ (1987) Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease. N Engl J Med 316:831-834
35. Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V, Weiner DM, Tison F, Bezard E (2011) Priorities in Parkinson's disease research. Nat Rev Drug Discov 10:377-393
36. Mendez I, Vinuela A, Astradsson A, Mukhida K, Hallett P, Robertson H, Tierney T, Holness R, Dagher A, Trojanowski JQ, Isacson O (2008) Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med 14:507-509
37. Nikkhah G (2001) Transplantation of embryonic dopamine neurons for severe Parkinson's disease: potential and pitfalls. Brain Res Bull 56:509
38. Nikkhah G, Falkenstein G, Rosenthal C (2001) Restorative plasticity of dopamine neuronal transplants depends on the degree of hemispheric dominance. J Neurosci 21:6252-6263
39. Nikkhah G, Rosenthal C, Falkenstein G, Roedter A, Papazoglou A, Brandis A (2009) Microtransplantation of dopaminergic cell suspensions: further characterization and optimization of grafting parameters. Cell Transplant 18:119-133
40. Novelli A, Reilly JA, Lysko PG, Henneberry RC (1988) Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 451:205-212
41. Olanow CW (1997) Attempts to obtain neuroprotection in Parkinson's disease. Neurology 49:S26-S33
42. Olanow CW, Jenner P, Brooks D (1998) Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol 44:S167-S174
43. Olanow CW, Koller W, Goetz CG, Stebbins GT, Cahill DW, Gauger LL, Morantz R, Penn RD, Tanner CM, Klawans HL, Shannon KM, Comella CL, Witt T (1990) Autologous transplantation of adrenal medulla in Parkinson's disease. 18-month results. Arch Neurol 47:1286-1289
44. Olanow CW, Mytilineou C, Tatton W (1998) Current status of selegiline as a neuroprotective agent in Parkinson's disease. Mov Disord 13(Suppl 1):55-58
45. Quinn N (1997) Parkinson's disease: clinical features. In: Quinn N (ed) Clinical neurology. Parkinsonism. Bailliere Tindall, London, pp 1-13
46. Rodriguez MC, Obeso JA, Olanow CW (1998) Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 44:S175-S188
47. Roedter A, Winkler C, Samii M, Nikkhah G (2000) Complex sensorimotor behavioral changes after terminal striatal 6-OHDA lesion and transplantation of dopaminergic embryonic micrografts. Cell Transplant 9:197-214
48. Schapira A (1997) Pathogenesis of Parkinson's disease. In: Quinn N (ed) Clinical neurology. International practice and research. Parkinsonism. Bailliere Tindall, London, pp 15-36
49. Singec I, Jandial R, Crain A, Nikkhah G, Snyder EY (2007) The leading edge of stem cell therapeutics. Annu Rev Med 58: 313-328
50. Singec I, Knoth R, Meyer RP, Maciaczyk J, Volk B, Nikkhah G, Frotscher M, Snyder EY (2006) Defining the actual sensitivity and specificity of the neurosphere assay in stem cell biology. Nat Methods 3:801-806
51. Smith GS, Laxton AW, Tang-Wai DF, McAndrews MP, Diaconescu AO, Workman CI, Lozano AM (2012) Increased cerebral metabolism after 1 year of deep brain stimulation in Alzheimer disease. Arch Neurol. doi: 10.1001/archneurol.2012.590
52. Wichmann T, Bergman H, DeLong MR (1994) The primate subthalamic nucleus. I. Functional properties in intact animals. J Neurophysiol 72:494-506
53. Wichmann T, Bergman H, DeLong MR (1994) The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism. J Neurophysiol 72:521-530
54. Winkler C, Kirik D, Bjorklund A (2005) Cell transplantation in Parkinson's disease: how can we make it work? Trends Neurosci 28:86-92
55. Winkler C, Sauer H, Lee CS, Björklund A (1996) Short-term GDNF treatment provides long-term rescue of lesioned nigral dopamine neurons in a rat model of Parkinson's disease. J Neurosci 16: 7206-7215